Through its activation of the p27Kip1 and p53–p21WAF1/Cip1 pathways, KPT-330 demonstrates its capability to induce cell death and halt cell proliferation in CTCL cells. The gene discussed is CDKN1A; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.